Cannabinoid Derived Pharmaceutical Market Size is valued at USD 12.6 Billion in 2024 and is predicted to reach USD 81.1 Billion by the year 2034 at an 20.8% CAGR during the forecast period for 2025-2034.
Cannabinoids are naturally occurring compounds derived from the Cannabis sativa plant. In recent years, Cannabinoids/medical marijuana have witnessed increased attention due to its growing therapeutic applications in human medicine. Cannabinoid’s active components are potentially effective in treating a variety of conditions, including chronic pain, cancer pain, depression, anxiety disorders, sleep disturbances, and neurological disorders. The recent upsurge in the use and acceptance of CBD can be principally attributed to the onset of cannabis legalization across the United States. Most recently, the passage of the 2018 Farm Bill, which legalized the cultivation of hemp – cannabis with less than 0.3 percent THC by weight.
The demand for cannabinoid extracts and isolates is expected to grow exponentially in the coming years, on account of the anticipated shift in consumer preferences for derivative cannabis product formats, and the applications for cannabinoids in pharmaceutical applications. The market is also driven by growing awareness about the therapeutic benefits paired with healing properties associated with cannabidiol (CBD). Moreover, cannabidiol (CBD) is widely used in several medical applications such as treatment of anxiety and depression, stress relief, diabetes prevention, mitigation of pain, alleviation of cancer symptoms, and acne reduction. The market is expected to show lucrative opportunities over the forecast period owing to the augmented adoption of CBD-based products for treating various medical conditions.
The global Cannabinoid Derived Pharmaceutical market is segmented on the basis of product, application, and region. Based on the products, the market is divided into Cannabinoid Receptor Type 1 (CB1), Cannabinoid Receptor Type 2 (CB2), and Others. On the basis of application type, the market is segmented into Alzheimer’s Disease, Autism, Cancer, Chronic Pain, Epilepsy, Migraine, Multiple Sclerosis, Schizophrenia, and Others. By Formulation segment the market is divided into Oils and Tinctures, Capsules and Tablets, Oral Sprays, Topicals, Others. The Cannabinoid Type category comprises Cannabidiol (CBD), Tetrahydrocannabinol (THC), Others. Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among that, Europe held the largest share of the market, followed by America and Asia Pacific. On the other hand, North America is expected to dominate the market during the analysis of the forecast period.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 12.6 Bn |
| Revenue Forecast In 2034 | USD 81.1 Bn |
| Growth Rate CAGR | CAGR of 20.8% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Product, By Molecule Type, By Disease Indication, by cannabinoid type, by formulation, By Application, By Source |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; Japan; Brazil; Mexico ; France; Italy; Spain; China; Japan; India; South Korea; South East Asia |
| Competitive Landscape | Cara Therapeutics, Inc., Arena Pharmaceuticals, Cannabics Pharmaceuticals Inc., Echo Pharmaceuticals, GW Pharmaceuticals, InMed Pharmaceuticals, INSYS Therapeutics, Inc., LaraPharm, MGC Pharmaceuticals, Ltd., One World Cannabis, Orpheus Medica, Receptor Life Sciences, RespireRx Pharmaceuticals, Tetra Bio-Pharma, Cardiol Therapeutics, United cannabis Corporation, Zynerba Pharmaceuticals, and List of Other Prominent Players. |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Cannabinoid Derived Pharmaceutical Market Snapshot
Chapter 4. Global Cannabinoid Derived Pharmaceutical Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Global Cannabinoid Derived Pharmaceutical Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.10. Use/impact of AI on Cannabinoid Derived Pharmaceutical Market Industry Trends
Chapter 5. Cannabinoid Derived Pharmaceutical Market Segmentation 1: By Products, Estimates & Trend Analysis
5.1. Market Share by Products, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Products:
5.2.1. Natural (Plant-Derived Cannabinoids)
5.2.1.1. Epidiolex
5.2.1.2. Sativex
5.2.1.3. Other Pipeline Products
5.2.2. Synthetic Cannabinoid
5.2.2.1. Marinol (dronabinol)
5.2.2.2. Syndros (dronabinol)
5.2.2.3. Cesamet (nabilone)
5.2.2.4. Other Pipeline Products
Chapter 6. Cannabinoid Derived Pharmaceutical Market Segmentation 2: By Molecule Type, Estimates & Trend Analysis
6.1. Market Share by Molecule Type, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Molecule Type:
6.2.1. Cannabinoid Receptor Type 1 (CB1)
6.2.2. Cannabinoid Receptor Type 2 (CB2)
6.2.3. Dual / Non-Selective Receptor Modulators
Chapter 7. Cannabinoid Derived Pharmaceutical Market Segmentation 3: By Cannabinoid Type, Estimates & Trend Analysis
7.1. Market Share by Cannabinoid Type, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Cannabinoid Type:
7.2.1. CBD-Based Pharmaceuticals
7.2.2. THC-Based Pharmaceuticals
7.2.3. Synthetic Cannabinoids
7.2.4. Minor Cannabinoids & Derivatives
7.2.5. Cannabinoid Receptor Modulators / Analogues
Chapter 8. Cannabinoid Derived Pharmaceutical Market Segmentation 3: By Therapeutic Indication / Application, Estimates & Trend Analysis
8.1. Market Share by Therapeutic Indication / Application, 2024 & 2034
8.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Therapeutic Indication / Application:
8.2.1. Neurological Disorders
8.2.2. Chronic Pain
8.2.3. Oncology / Cancer Supportive Care
8.2.4. Psychiatric & Behavioral Disorders
Chapter 9. Cannabinoid Derived Pharmaceutical Market Segmentation 3: By Route of Administration / Formulation, Estimates & Trend Analysis
9.1. Market Share by Route of Administration / Formulation, 2024 & 2034
9.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Route of Administration / Formulation:
9.2.1. Oral
9.2.2. Topical
9.2.3. Oral Spray
9.2.4. Inhalation
Chapter 10. Inflammatory & Autoimmune Diseases
Chapter 11. Cannabinoid Derived Pharmaceutical Market Segmentation 5: Regional Estimates & Trend Analysis
11.1. Global Cannabinoid Derived Pharmaceutical Market, Regional Snapshot 2024 & 2034
11.2. North America
11.2.1. North America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
11.2.1.1. US
11.2.1.2. Canada
11.2.2. North America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
11.2.3. North America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Molecule Type, 2021-2034
11.2.4. North America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Cannabinoid Type, 2021-2034
11.2.5. North America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Indication / Application, 2021-2034
11.2.6. North America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration / Formulation, 2021-2034
11.3. Europe
11.3.1. Europe Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
11.3.1.1. Germany
11.3.1.2. U.K.
11.3.1.3. France
11.3.1.4. Italy
11.3.1.5. Spain
11.3.1.6. Rest of Europe
11.3.2. Europe Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
11.3.3. Europe Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Molecule Type, 2021-2034
11.3.4. Europe Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Cannabinoid Type, 2021-2034
11.3.5. Europe Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Indication / Application, 2021-2034
11.3.6. Europe Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration / Formulation, 2021-2034
11.4. Asia Pacific
11.4.1. Asia Pacific Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
11.4.1.1. India
11.4.1.2. China
11.4.1.3. Japan
11.4.1.4. Australia
11.4.1.5. South Korea
11.4.1.6. Hong Kong
11.4.1.7. Southeast Asia
11.4.1.8. Rest of Asia Pacific
11.4.2. Asia Pacific Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
11.4.3. Asia Pacific Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Molecule Type, 2021-2034
11.4.4. Asia Pacific Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Cannabinoid Type, 2021-2034
11.4.5. Asia Pacific Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Indication / Application, 2021-2034
11.4.6. Asia Pacific Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration / Formulation, 2021-2034
11.5. Latin America
11.5.1. Latin America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
11.5.1.1. Brazil
11.5.1.2. Mexico
11.5.1.3. Rest of Latin America
11.5.2. Latin America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
11.5.3. Latin America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Molecule Type, 2021-2034
11.5.4. Latin America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Cannabinoid Type, 2021-2034
11.5.5. Latin America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Indication / Application, 2021-2034
11.5.6. Latin America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration / Formulation, 2021-2034
11.6. Middle East & Africa
11.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
11.6.1.1. GCC Countries
11.6.1.2. Israel
11.6.1.3. South Africa
11.6.1.4. Rest of Middle East and Africa
11.6.2. Middle East & Africa Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
11.6.3. Middle East & Africa Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Molecule Type, 2021-2034
11.6.4. Middle East & Africa Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Cannabinoid Type, 2021-2034
11.6.5. North America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Indication / Application, 2021-2034
11.6.6. Middle East & Africa Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration / Formulation, 2021-2034
Chapter 12. Competitive Landscape
12.1. Major Mergers and Acquisitions/Strategic Alliances
12.2. Company Profiles
12.2.1. Jazz Pharmaceuticals plc (via GW Pharmaceuticals — Epidiolex, Sativex)
12.2.2. AbbVie Inc.
12.2.3. Bausch Health Companies Inc.
12.2.4. Botanix Pharmaceuticals Ltd.
12.2.5. Kannalife Sciences Inc.
12.2.6. Aphios Pharma LLC
12.2.7. Tilray Brands, Inc. (Tilray Medical)
12.2.8. Panaxia Pharmaceutical Industries Ltd.
12.2.9. Enveric Biosciences, Inc.
12.2.10. ZYUS Life Sciences Inc.
12.2.11. Skye Bioscience, Inc.
12.2.12. Teon Therapeutics, Inc.
12.2.13. CURE Pharmaceutical Corporation
12.2.14. CB Therapeutics Inc.
12.2.15. Ananda Pharma plc
12.2.16. MIRA Pharmaceuticals, Inc.
12.2.17. Anebulo Pharmaceuticals, Inc.
12.2.18. Cronos Group Inc.
12.2.19. Aurora Cannabis Inc.
12.2.20. Canopy Growth Corporation
12.2.21. Curaleaf Holdings, Inc.
12.2.22. Trulieve Cannabis Corp.
12.2.23. Green Thumb Industries Inc.
12.2.24. Others
12.2.25. Avecho Biotechnology Ltd.
12.2.26. Other Prominent Players
Global Cannabinoid Derived Pharmaceutical Market, by Products, 2025-2034 (Value US$ Mn)
· Natural (Plant-Derived Cannabinoids)
o Epidiolex
o Sativex
o Other Plant-Derived Pipeline Products
· B. Synthetic Cannabinoids
o Marinol
o Syndros
o Cesamet
o Other Synthetic Pipeline Products
Global Cannabinoid Derived Pharmaceutical Market, by Molecule Type, 2025-2034 (Value US$ Mn)
· Cannabinoid Receptor Type 1
· Cannabinoid Receptor Type 2
· Dual / Non-Selective Receptor Modulators
· Others
Global Cannabinoid Derived Pharmaceutical Market, by By Source / Origin
· Plant-Derived Cannabinoids
· Synthetic Cannabinoids
Global Cannabinoid Derived Pharmaceutical Market, by Disease Indication, 2025-2034 (Value US$ Mn)
Global Cannabinoid Derived Pharmaceutical Market, by Formulation
· Oral
· Topical
· Oral Sprays
· Inhalation / Vaporization
· Others
Global Cannabinoid Derived Pharmaceutical Market, by Cannabinoid Type
· CBD-Based Pharmaceuticals
· THC-Based Pharmaceuticals
· Synthetic Cannabinoids
· Minor Cannabinoids & Derivatives
· Cannabinoid Receptor Modulators / Analogues
Global Cannabinoid Derived Pharmaceutical Market, By Distribution Channel
· Hospital Pharmacies
· Retail Pharmacies / Drug Stores
Global Cannabinoid Derived Pharmaceutical Market, By Therapeutic Indication / Application
· Neurological Disorders
· Chronic Pain
· Oncology / Cancer Supportive Care
· Psychiatric & Behavioral Disorders
· Inflammatory & Autoimmune Diseases
Global Cannabinoid Derived Pharmaceutical Market, by Region,
North America Cannabinoid Derived Pharmaceutical Market, by Country,
Europe Cannabinoid Derived Pharmaceutical Market, by Country,
Asia Pacific Cannabinoid Derived Pharmaceutical Market, by Country,
Latin America Cannabinoid Derived Pharmaceutical Market, by Country,
Middle East & Africa Cannabinoid Derived Pharmaceutical Market, by Country,